PCAST Co-Chair Encourages Observation Of Antibiotic Therapeutic Use In WH Action Plan

A White House action plan to address antibiotic-resistant bacteria released Friday (March 27) relies on FDA’s guidance that has manufacturers voluntarily revise FDA-approved use conditions on labels of medically important antibiotics to remove production indications. In that agency guidance, an FDA official said all affected companies are willing to align their practices with FDA guidelines by December 2016. However, stakeholders have additionally called for the administration to review antibiotic use in disease prevention saying a loophole in this area means...